Global Director Pipeline Biosimilar Platform; d​/f​/m

Job Description Summary We are hiring Job Description Sandoz continues to go through an exciting and transformative period as a global leader and pioneering provider of sustainable Biosimilar and Generic medicines. As we continue down this new and ambitious path, unique opportunities will present themselves, both professionally and personally. Join us, the future is ours to shape! In this role, you’ll shape the future of our global biosimilar pipeline.

As Global Director Pipeline Biosimilar Platform, you’ll sit at the crossroads of science, commercial strategy, and investment decisions—helping determine which biosimilar assets we invest in, when, and at what scale. You’ll work closely with commercial, R&D, regulatory, market access, manufacturing, and competitive intelligence teams to ensure our portfolio choices are scientifically sound, commercially attractive, and aligned with long‑term strategy. In a fast‑evolving biosimilar landscape with shorter life cycles and shifting global dynamics, you’ll help keep us ahead of the curve and deliberate in where we place our bets.

• Shaping global biosimilar pipeline strategy, including molecule/platform selection and portfolio balancing.
• Building differentiated perspectives (thought‑leadership) on emerging technologies, disease trends, and global market evolution.
• Strengthening Analytical, Financial & Risk Discipline by:
  Driving rigorous forecasting, valuation, and scenario planning—incorporating development risk, commercial uncertainty, IP dynamics, and competitive threat modelling.
• Providing senior leadership with transparent, evidence‑based investment cases.

• Navigating increasing scientific and commercial complexity driven by new therapeutic modalities and expanding target spaces.
• Ensuring adaptability to regulatory shifts, policy changes, and evolving standards of care—protecting investment decisions and maximizing the value of future launches.
• Guiding early commercial strategy, including competitive Target Product Profile development.

• A business and/or science background and degree is required.
• MD, science PhD, MBA or equivalent experience is desirable.
• Minimum 12 years pharma industry expertise required.
• Strong specialty care and biologics background (oncology, immunology, rare diseases).
• Ability to integrate scientific assessments, market trends, competitive threats, and evolving policy landscapes into clear strategic recommendations.
• Expertise in shaping future‑ready portfolios, including molecule/platform selection, portfolio balancing, and prioritization.
• Ability to project commercial potential, design competitive TPPs, and anticipate unmet needs or access barriers.
• Demonstrated expertise in portfolio strategy, forecasting, valuation, and risk assessment.
• Extensive commercial experience in global or major markets (e.g., Business Franchise Head, TA Lead, Director Strategy, Access).
• Experience leading cross functional teams and influencing senior decision making.
• Direct people leadership experience is strongly preferred.
• Strong communicator, capable of presenting complex decisions and recommendations to executive committees with clarity and conviction.
• Fluent English (written and spoken).
• Additional languages are beneficial.

Sandoz compensation is determined by job level, qualifications, niche skills, experience, and location within company salary ranges. Fully proficient and highly effective employees can expect a starting salary around market median, with those new to the level or with less functional depth at the lower end of the range and those with sustained superior or niche skills towards the higher end of the range.

Internal equity and external market data inform our range placement. Annual salary reviews consider performance outcomes, market alignment, and business needs.

Generic and Biosimilar medicines are the backbone of the global medicines industry. Sandoz, a leader in this sector, provided more than 900 million patient treatments across 100+ countries in 2024 and while we are proud…